Slide 1: Investor Presentation May 2, 2025
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation May 2, 2025
Slide 2: Disclaimer: Forward-Looking Statements and Market Data
Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “Company” or “Fulgent”) about future events based o
Slide 3: Leadership Team
Leadership Team Seasoned legal and privacy professional with nearly two decades of legal experience Privacy Law Specialist; Certified Information Privacy Manager; Certified Information Privacy Professional and an Advisory Board Member with the International Association of Privacy Professionals J.D.
Slide 4: About Fulgent
About Fulgent We are a premier global, technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Mission Develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those aroun
Slide 5: Laboratory Services
LABORATORY SERVICES
Slide 6: Positioned for Growth
Well-positioned to execute on a growth strategy that includes organic and inorganic initiatives, including: Transformational acquisition of Inform Diagnostics Ramping of CSI Labs Scaling partnerships Potential future acquisitions with a strategy of short- and long-term ROI, tangible synergies, and e
Slide 7: Platform and Capabilities Across Divisions
Platform and Capabilities Across 3 Divisions Precision Diagnostics Reproductive Health Oncology / Liquid Biopsy Rare Disease Neurogenetics BioPharma Services Anatomic Pathology Laboratory Services Dermatopathology GI GU GSP Spatial Phenotyping Exome/Genome sequencing RNA sequencing Single Cell seque
Slide 8: Target Market Opportunity
Target Market Opportunity Cancer Diagnostics $80B market1 Market sizes sourced from Wall Street equity research Market size sourced from Frost & Sullivan, October 2022 Market size sourced from Research and Markets, April 2022 $18B market1 Early Detection / Liquid Biopsy Reproductive Health $8B marke
Slide 9: What Sets Fulgent Diagnostics Apart?
What Sets Fulgent Diagnostics Apart? Technology Platform A New Approach to NGS Proprietary probes and engineered chemistry Comparison and suppression algorithms Comprehensive analytics powered by AI and ML Extensive Test Menu Leads to a Broader Test Menu 18,400+ single-gene tests (1) 900+ panels Who
Slide 10: Proprietary Technology Platform
Patients and Providers Research Portal …Provides a Multitude of Advantages Broad test menu Ability to rapidly develop and launch new tests Customizable test offerings Lower costs per billable test High efficiency Proprietary Technology Platform Differentiated Technology... Engineered genetic biochem
Slide 11: Comprehensive Anatomic Pathology Services
Comprehensive Anatomic Pathology Services Specialized Oncology Testing Recent Traction with: Hereditary Cancer Cardiovascular Genetics Reproductive Health Neurodegenerative Genetics Newly launched pharmacogenetic test Aggressively expanding sales and commercial organization Wide Array of Technologie
Slide 12: Scalable and Affordable Menu for Customers
Scalable and Affordable Menu for Customers Large Panel Small Panel Focus Panel Single-Gene / Custom Comprehensive Panel Average Sales Price / Test Whole Genome Whole Exome Clinical Exome GREATER OFFERINGS THAN LEADING COMPETITORS CNV+ MANY COMPETITORS DO NOT OFFER Flow Cytometry FISH Histopathology
Slide 13: NGS Testing – Offerings
NGS Testing – Offerings Site-Specific Testing Known Mutation Focus (49 Genes) Comprehensive (153 Genes) Somatic Cancer Panels 20 Panels Repeat Expansion 18,400+ Genes Single Gene 800+ Panels Customizable Panels Disease Panels Clinical Exome (4,500+ Genes) Whole Exome Exome Tests
Slide 14: NGS Testing – Germline Oncology Test Menu
NGS Testing – Germline Oncology Test Menu Fulgent Focus Cancer Panels Fulgent Comprehensive Cancer Panels Customizable: Add additional cancer genes or panels at no charge Genes: 49 Methods: NGS & Del/Dup Coverage: 99% at 50x Del/Dup ≥ 1 Exon TAT: 2 – 3 Weeks Customizable: Add additional cancer genes
Slide 15: Oncology Testing Platforms
Oncology Testing Platforms Expansive heme and solid tumor menu STAT testing available - PML/RARA <1 day TAT CD138 cell enrichment for PCM 3-5 day turnaround time 225+ stains Platform agnostic Roche, Agilent and Leica IHC Three levels of service – Tech, Global, Consultative PD-L1 - Various IVD platfo
Slide 16: NGS Testing – Rapid Whole Genome
NGS Testing – Rapid Whole Genome Covers >4,000 single gene disorders Fast turn around time (7-10 days) Focused reporting of diagnostic findings only Designed for critically ill infants in the NICU/PICU to rapidly diagnose genetic disorders Multiple congenital anomalies Inborn errors of metabolism Im
Slide 17: NGS Testing – Panel Deep Dive
The Focus Carrier screen is a pan-ethnic screen that looks for pathogenic mutations known to cause autosomal recessive and X-linked disorders Gene Count: 30 The Ashkenazi Jewish carrier screens for pathogenic carrier variants known to cause recessive genetic disorders Gene Count: 61 The ACOG/ACMG pa
Slide 18: Prenatal Screening for Genetic Conditions
Prenatal Screening for Genetic Conditions
Slide 19: Technology: NGS Comprehensive NIPS
Technology NGS Comprehensive NIPS utilizing coordinative allele-aware target enrichment (COATE) suppresses allelic hybridization bias Dual end sequencing retains cfDNA fragmentation characteristics Multi-dimensional analyses for allelic ratios, read-depth, cfDNA fragmentation pattern KNOVA technolog
Slide 20: Fulgent NIPT/NIPS – Full Panel
Fulgent NIPT/NIPS – Full Panel Aneuploidies - 6 13, 15, 16, 18, 21, 22 Aneuploidies (sex chr) Monosomy X (Turner), XXY (Kleinfelter), XXX (Triple X), XYY (Jacob) Microdeletions - 12 1p36; 2q33.1; 4p16; 5p15; 8q23; 9p; 11q23-25; 15q11.2-q13; 17p11.2; 18q; 18p; 22q11.2 Single genes - 56 ASXL1, BRAF, C
Slide 21: Detection Rates of KNOVA in High-Risk Pregnancies
Detection Rates of KNOVA in High-Risk Pregnancies Aneuploidies - 6 13, 15, 16, 18, 21, 22 Aneuploidies (sex chr) Monosomy X (Turner), XXY (Kleinfelter), XXX (Triple X), XYY (Jacob) Microdeletions - 12 1p36; 2q33.1; 4p16; 5p15; 8q23; 9p; 11q23-25; 15q11.2-q13; 17p11.2; 18q; 18p; 22q11.2 Single genes
Slide 22: Consumer Initiated Tests – Picture Genetics
Parenting Screens adults to determine their carrier status for recessive genetic disorders Newborn Screens newborns for genes associated with various severe genetic conditions Wellness Screens adults for genetic variants that indicate disease risk PD Aware Assesses genetic risk for Parkinson's Disea
Slide 23: Therapeutic Development
THERAPEUTIC DEVELOPMENT
Slide 24: Nano-Drug Delivery Platform Overview
Nano-Drug Delivery Platform Overview Many drug candidates in the industry failed during preclinical and clinical development and testing due to poor water solubility Nanoencapsulation produces amorphous drug candidates with improved solubility and potentially enhanced absorption, drug PK profiles, s
Slide 25: FID-007 Program Overview
FID-007 Program Overview Note: all findings are preliminary DCR includes Stable Disease (SD), Partial Response (PR), Complete Response (CR) FID-007 Phase 1/1b Preliminary Highlights (as of 6/2/24): H&N Cancer 45% ORR and 72% DCR were observed in 11 heavily treated HNSCC patients. Among them, 3 out o
Slide 26: FID-007 Clinical Data Presented at ASCO 2024
FID-007 Clinical Data Presented at ASCO 2024
Slide 27: Potential Market Opportunity for FID-007
Potential Market Opportunity for FID-007 Pancreatic $1.23B in 2024 $1.53B by 2035 NSCLC $184M in 2024 $210M by 2035 Ampullary2 $12M in 2024 $10M by 2035 H&N1 $1.84B in 2024 $2.1B by 2035 Note: U.S. opportunity shown Sources: Evaluate Pharma, Wall Street research, and management pricing expectations
Slide 28: Pipeline Progress
Pipeline Progress FID-007: wholly-owned drug candidate initially focused on Head & Neck (H&N), Pancreatic/Ampullary cancers Phase 2 trial ongoing for 2nd line treatment of H&N cancer FID-022 IND submitted and approved; Phase 1 to begin in 2Q25 Potential FDA approval strategy uses 505(b)(2) studies,
Slide 29: Financials
FINANCIALS
Slide 30: Summary Financial Performance
Summary Financial Performance $73M Core Revenue1 in Q1’25 $9M Last Twelve Months (LTM) Operating Cash Flow as of Q1’25 16% growth year-over-year Core Revenue excludes NGS COVID-19 test volume +11% year-over-year ($ in thousands)
Slide 31: Financial Performance: Revenue and Gross Margin
Financial Performance: Revenue and Gross Margin Core Revenue excludes NGS COVID-19 test volume ($ in thousands) ($ in thousands) ($ in thousands)
Slide 32: 2025 Financial Guidance
2025 Financial Guidance Core Revenue excludes NGS COVID-19 test revenue for more accurate year over year comparison purposes. Cash expenditures may be higher or lower than currently estimated due to a variety of facts and circumstances, including as a result of the Company’s ongoing stock repurchase
Slide 33: Balance Sheet
Balance Sheet (in 00 Periods Ended December 31, 2024 Ma 31, 2025 Cash & cash equivalents $ 55,144 § 67,281 Marketable securities 202,962 253,040 “ Trade accounts receivable, net 69,021 71,478 Other current assets. 26,444 24,985 Total current assets 353,571 416,784 Marketable securities, long-term 57
Slide 34: Non-GAAP Financial Adjustments
Non-GAAP Financial Adjustments
Slide 35: Thank You
THANK YOU
Slide 36: Founded in 2011 | Located in El Monte, CA
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT